| Document |
Document Title |
|
JP3490757B2 |
PURPOSE: To provide the activating agent containing a saponin compound as an active ingredient, exhibiting an excellent neutrophilic function-increasing action, high in safety, easy in the acquisition of raw materials, and expected as an...
|
|
JP3468211B2 |
To provide an intermediate capable of giving a (+)-estrone derivative from a dicyclopentadiene derivative with small number of steps in high total yield. The objective compound of formula (R is a 1-20C alkyl) can be produced by using (-)...
|
|
JP3453188B2 |
PURPOSE: To industrially and advantageously obtain an oleanolic acid useful as a production intermediate, etc., for endothelin receptor antagonism, etc., by reducing a specific steroidal lactone compound with an alkali(earth)metal in an ...
|
|
JP2003522728A |
Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.
|
|
JP3418428B2 |
PURPOSE: To provide the novel steroid compounds whose steroid skeleton is bound at carbon atom 17 to a spiromethylene ring having progestational activity and antiprogenstational activities, and useful as contraceptive medicines. CONSTITU...
|
|
JP2003515543A |
The disclosed invention relates to the unexpected finding of novel steroids which are characterized by a 14beta,15beta-cyclopropane ring and a 17alpha hydroxymethyl group. These steroids according to the invention are found to have in co...
|
|
JP2003505393A5 |
|
|
JP2003505393A |
The invention relates to new C-19-halogen-substituted steroids of the androst-9(11)-ene series, namely 17beta-hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones of general formula (I) and process for their production. In addition, the use o...
|
|
JP2002544136A |
The present invention relates to pharmaceutically active 14 beta -H-sterols, to pharmaceutical compositions comprising them and to the use of these novel compounds for the preparation of medicaments. More particularly it has been found t...
|
|
JP3359774B2 |
An external preparation for skin comprising at least one member selected from the group consisting of escinol and its salts represented by the following constitutional formula (1): (wherein R<1> is hydrogen atom or hydroxyl group and R<2...
|
|
JP2002540119A |
The invention provides compositions comprising formula 1 steroids, e.g., 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. Th...
|
|
JP2002536455A |
3,16-Dihydroxy-1,3,5(10)-estratriene derivatives (I) are new. 3,16-Dihydroxy-1,3,5(10)-estratriene derivatives of formula (I) are new: [Image] thick black line in ring = single or double bond; R 1>H, halo, OH, Me, CF 3, OMe or OEt; R 2>H...
|
|
JP3333524B2 |
Production of drospirenone (6beta ,7beta ;15beta ,16beta -dimethylene-3-oxo-17alpha -pregn-4-ene-21,17-carbolactone) of formula (I) comprises catalytically hydrogenating 17alpha -(3-hydroxy-1-propynyl)-6beta ,7beta ;15beta ,16beta -dimet...
|
|
JP3328377B2 |
PURPOSE: To economically obtain the subject compd. showing therapeutic activity without producing by-products by a new method of inverting a specified starting compd. into a halohydrin, rearranging the halohydrin in the presence of an al...
|
|
JP3302366B2 |
In this invention, the new etheno- and ethano-19,11-bridged 4-estrenes of general formula I (I) are described, in which W, R1, R2, R6a, R6b, R7, R14, R15, R16, R11, R11' and R19 have the meaning indicated in the description, as well as a...
|
|
JP3295426B2 |
Novel antihypercholesterolemic agents are provided. An exemplary group of compounds has the structural formula (I) (I) wherein R is a C-17 side chain, R1 is -OH, =O, or the like, and X and Y are CH, C-OH, C-OCH3 or C-Z. Methods of using ...
|
|
JP3273010B2 |
To obtain a compound useful for treating a disease corresponding to a sex steroid. This sex steroid inhibitor has a molecular structure of formula I (a dotted line is a double bond; R5 and R6 are each H, hydroxyl, etc.; R100 is a divalen...
|
|
JP2002060384A |
To obtain a compound useful for treating breast cancer or other diseases promoted by their exacerbation due to the activation of sex steroid receptor, and to provide a medicament composition containing the above compound.This compound ha...
|
|
JP2002505292A |
A series of novel steroid derivatives are described. The steroid derivatives are antibacterial agents. The steroid derivatives also act to sensitize bacteria to other antibiotics including erythromicin and novobiocin.
|
|
JP2002505337A |
Betulin and dihydrobetulin acyl derivatives according to the present invention have been found to have potent anti-HIV activity. The compounds of the present invention have the following formulae:or pharmaceutically acceptable salts ther...
|
|
JP2002505337A5 |
|
|
JP2002502406A |
This invention describes 11beta-aryl-substituted 14,17-ethanoestratrienes of general formula (I). The new compounds are selective estrogens whose action occurs in a tissue-selective manner. The estrogenic action occurs in particular on b...
|
|
JP2002500190A |
This invention provides novel compounds derived from a marine sponge, Adocia sp., that specifically modulat kinesin activity by targeting the kinesin motor domain and mimicking the activity a microtubule. The compounds act as potent anti...
|
|
JP2001525334A |
The invention relates to novel 15-methyl-cyclopropanosteroids of general formula (I), wherein R1 represents a hydrogen atom, an alkyl group, an acyl group, or a sulfamoyl group, R2 and R3 represent independently from each other a hydroge...
|
|
JP3237722B2 |
PURPOSE: To provide new antibiotic substances Mer-NF8054A and X useful as an antimycotic agent and producible by culturing a microbial strain belonging to the genus Aspergillus and capable of producing the antibiotic substance Mer-NF8054...
|
|
JP3202229B2 |
PCT No. PCT/EP91/02239 Sec. 371 Date Sep. 28, 1993 Sec. 102(e) Date Sep. 28, 1993 PCT Filed Nov. 27, 1991 PCT Pub. No. WO92/09618 PCT Pub. Date Jun. 11, 1992.8-En-19,11 beta -bridged steroids of general formula I (I) that have the 8,9-do...
|
|
JP2001509792A |
Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of Formula Iwherein-A-A- represents the group -CHR4-CHR5- or -CR4=CR5-;R3, R4 and R5 are in...
|
|
JP3178046B2 |
PURPOSE: To obtain the subject derivative in good yield in a few steps by using a specific compound as a starting substance and subjecting the compound and a 4-vinyl-7-alkoxy-1,2-dihydronaphthalene to the asymmetric Diels-Alder reaction....
|
|
JP2001505212A |
Steroid esters of formula I are described, wherein m, n and x are as defined by the specification. The compounds are distinguished from the basic hydroxy compounds by considerably improved solubility as well by increased biological activ...
|
|
JP3143876B2 |
The present invention is directed to a group of androstane compounds which contain an ethylene radical bridging the 2- and 19-positions. These compounds are useful as aromatase inhibitors and they are prepared by the cyclization of a 19-...
|
|
JP2001503024A |
The present invention describes new substituted 7T-(--aminoalkyl)-estratrienes of general formula (I), in which the side chain SK is a radical of partial formula (II), where m equals 4, 5 or 6; n equals 0, 1 or 2; x equals 0, 1 or 2; A i...
|
|
JP3135564B2 |
11 beta -substituted-16 alpha , 17 alpha -methylene-estra-4,9-dien-3-ones of formula I (I) wherein R1 is a methyl or ethyl group; R2 is H; a C1-6-alkyl, -alkoxymethyl, -alkanoyl or -alkoxcarbonyl group ; 2-methoxyethyl; 2-hydroxyethyl; 2...
|
|
JP2000256390A |
To obtain a medicine composition useful for treating diseases related to estrogen and androgen by making the composition include a pharmacologically acceptable diluent, or the like, and a specific sex steroid activity inhibitor. This com...
|
|
JP3061856B2 |
11(+)-Aryl-16 alpha ,17 alpha -cyclohexano-estra-4,9-dienes of formula wherein R1 is H or a methyl group; R2 is -OCH3, -SCH3, -N(CH3)2, -NHCH3, -CN, -CHO, -COCH3 or -CHOHCH3; X is -CHO, -COCH3, -CH2OH, -CHOHCH3, -CH2CHO-C1-7-alkyl, -CH2C...
|
|
JP2000504025A |
The invention relates to a method of altering the blood levels of LH or FSH in an individual. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithel...
|
|
JP2000038392A |
To provide a novel compound that is useful as a linker for silicon base over a wide range of solid-phase syntheses, can be synthesized through a relatively simple process and can bond the ligand molecule to the solid-phase support before...
|
|
JP2996723B2 |
New 14alpha, 17alpha-bridged oestratrienes of formula (I) are claimed. When OR3 is in the alpha-configuration: R1, R2, R3 = H, -CO-R4 or -(CH2)n-CO2H, where n = 1-4. R1 may also be benzyl, 1-8C alkyl or 3-5C cycloalkyl; R4 = an organic g...
|
|
JP2980389B2 |
Products of formula (I): in which =X denotes =O or R = H or acyl and the broken lines show the optional presence of one or two additional double bonds, process for their preparation and intermediates of this process, their application as...
|
|
JPH11511457A |
PCT No. PCT/SE96/01028 Sec. 371 Date Apr. 23, 1997 Sec. 102(e) Date Apr. 23, 1997 PCT Filed Aug. 20, 1996 PCT Pub. No. WO97/08188 PCT Pub. Date Mar. 6, 1997Compounds of the formula I a process for their preparation, their use in the trea...
|
|
JP2953725B2 |
A 11 beta -aryl-19-norprogesterone steroid of the formula: wherein (i) R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, OC(O)CH3, or OC(O)R5 , wherein R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl, R2 is H, R3 is H, C1-4 alkyl...
|
|
JPH11507360A |
Several 19-nor-pregnanes are provided which have the capacity to neurochemically alter the hypothalamic function in an individual through nasal administration. These pharmaceutically active compounds can be administered by themselves or ...
|
|
JP2860821B2 |
|
|
JP2848919B2 |
The use of preferably together with an oestrogen, for the preparation of a pharmaceutical which is suitable for the treatment of hormonal irregularities in the premenopause (cycle stabilisation) and for hormone replacement therapy in the...
|
|
JPH11500615A |
PCT No. PCT/FR96/00089 Sec. 371 Date Aug. 8, 1997 Sec. 102(e) Date Aug. 8, 1997 PCT Filed Jan. 19, 1996 PCT Pub. No. WO96/25512 PCT Pub. Date Aug. 22, 1996A Chrysosporium strain No. CBS 123.95, mutants and derivatives thereof, and a meth...
|
|
JPH11500133A |
Certain benzopyran antiestrogens are disclosed for treating estrogen sensitive diseases such as breast cancer. Prodrug forms provide ease of manufacturing, good shelf life, and bioavailibility.
|
|
JPH10511379A |
The invention describes 14,17-C2-bridged steroids of general formula (I), wherein the various R groups are as defined in the specification, and wherein said steroids are in contrast, with the disclaimed compound, the new compounds are av...
|
|
JPH10509423A |
The invention relates to estrene steroids, which bind to neuroepithelial cells in the human vomeronasal organ. The steroids are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically a...
|
|
JP2784846B2 |
Inhibitors of sex steroid activity, for example those having the general structure may be used as part of a pharmaceutical composition to provide antiestrogenic effects and/or to suppress estrogen synthesis. Such pharmaceutical compositi...
|
|
JP2760870B2 |
PCT No. PCT/EP89/01090 Sec. 371 Date Mar. 20, 1991 Sec. 102(e) Date Mar. 20, 1991 PCT Filed Sep. 20, 1989 PCT Pub. No. WO90/03385 PCT Pub. Date Apr. 5, 1990.New 11 beta -phenyl-14 beta H-steroids of general formula (I), where Z is an oxy...
|
|
JPH10101567A |
To obtain the subject composition enabling estrogen therapy and the supplement of estrogen to mammals, in which the increase of prolactin level accompanying estrogen administration is unwanted, by compounding dehydroestorone, etc., havin...
|
